Showing results (121-130 of 144) with videos related to
Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2024
Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b TrialShen Zhao, Huaqiang Zhou, Nong Yang, et al.JAMA|June 28, 2018
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical TrialJin Li, Shukui Qin, Rui-Hua Xu, et al.Investigational New Drugs|November 15, 2017
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancerXuenong Ouyang, Meiqi Shi, Fangwei Jie, et al.Advances in Therapy|September 9, 2020
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO TrialJin Li, Weijian Guo, Yuxian Bai, et al.Oncotargets and Therapy|August 19, 2021
Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal CancerShukui Qin, Rui-Hua Xu, Lin Shen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 12, 2020
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)Yunpeng Yang, Zhehai Wang, Jian Fang, et al.Signal Transduction and Targeted Therapy|June 29, 2023
Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II TrialShun Lu, Hongming Pan, Lin Wu, et al.Future Oncology (London, England)|December 16, 2020
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trialRuihua Xu, Shukui Qin, Weijian Guo, et al.The Lancet. Gastroenterology & Hepatology|May 10, 2021
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialShukui Qin, Qiu Li, Shanzhi Gu, et al.Journal of Hematology & Oncology|May 9, 2023
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumorsYuanyuan Zhao, Yuxiang Ma, Aimin Zang, et al.Pageof 15